Pharmalittle: Most drug price hikes occurred before Azar arrived; Novartis abandons antibiotics

first_imgPharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @Pharmalot Alex Hogan/STAT Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Ed Silverman Log In | Learn More What is it? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What’s included?center_img Tags drug pricinglegalpharmaceuticalspharmalittleSTAT+Trump Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Pharmalittle: Most drug price hikes occurred before Azar arrived; Novartis abandons antibiotics [email protected] GET STARTED About the Author Reprints Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. The short person has left for the local summer job and, as always, the official mascots are snoozing here and there. We, however, have no time to nap, since there is always much to be done. The world, after all, continues to spin no matter what. On that note, here are a few items of interest. Hope your day goes well and that you will reach out if anything interesting arises …Novartis (NVS) is closing its antibiotic and antiviral research operations in the San Francisco Bay area and cutting about 140 jobs, the latest big drug maker to abandon this field. The company, which is not abandoning research into tropical diseases such as malaria, is looking to license its early-stage products and stressed that its Sandoz generics unit continues to manufacture and sell antibiotics and antivirals. The Access to Medicines Foundation noted that Novartis had 32 antimicrobial research and development projects in its pipeline. By Ed Silverman July 12, 2018 Reprintslast_img

Posts Tagged with… , , , , , , , , , , ,

Write a Comment

Your email address will not be published. Required fields are marked *